Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma
Floros, K. V.; Fairchild, C. K.; Li, J.; Zhang, K.; Roberts, J. L.; Kurupi, R.; Hu, B.; Kraskauskiene, V.; Hosseini, N.; Shen, S.; Inge, M. M.; Smith-Fry, K.; Li, L.; Sotiriou, A.; Dalton, K. M.; Jose, A.; Abdelfadiel, E. I.; Xing, Y.; Hill, R. D.; Slaughter, J. M.; Shende, M.; Lorenz, M. R.; Hinojosa, M. R.; Belvin, B. R.; Lai, Z.; Books, S. A.; Stamatouli, A. M.; Lewis, J. P.; Manjil, M. H.; Valerie, K.; Li, R.; Banito, A.; Poklepovic, A.; Koblinski, J.; Siggers, T.; Dozmorov, M. G.; Jones, K. B.; Radhakrishnan, S. K.; Faber, A. C.
Show abstract
Synovial Sarcoma (SS) is driven by the SS18::SSX fusion oncoprotein. and is ultimately refractory to therapeutic approaches. SS18::SSX alters ATP-dependent chromatin remodeling BAF (mammalian SWI/SNF) complexes, leading to the degradation of canonical (cBAF) complex and amplified presence of an SS18::SSX-containing non-canonical BAF (ncBAF or GBAF) that drives an SS-specific transcription program and tumorigenesis. We demonstrate that SS18::SSX activates the SUMOylation program and SSs are sensitive to the small molecule SAE1/2 inhibitor, TAK-981. Mechanistically, TAK-981 de-SUMOylates the cBAF subunit SMARCE1, stabilizing and restoring cBAF on chromatin, shifting away from SS18::SSX-ncBAF-driven transcription, associated with DNA damage and cell death and resulting in tumor inhibition across both human and mouse SS tumor models. TAK-981 synergized with cytotoxic chemotherapy through increased DNA damage, leading to tumor regression. Targeting the SUMOylation pathway in SS restores cBAF complexes and blocks the SS18::SSX-ncBAF transcriptome, identifying a therapeutic vulnerability in SS, positioning the in-clinic TAK-981 to treat SS.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1 mediated reprogramming of bone mesenchymal stem cells 94%
- G9a Promotes Breast Cancer Recurrence Through Repression of a Pro-inflammatory Program 94%
- Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1 94%
Similar papers in this journal
- NAB2-STAT6 drives an EGR1-dependent neuroendocrine program in Solitary Fibrous Tumors 94%
- Loss of MGA mediated Polycomb repression promotes tumor progression and invasiveness 94%
- Exosome component 1 cleaves single-stranded DNA and sensitizes kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor 94%
Similar papers in this journal
- IWS1 phosphorylation promotes cell proliferation and predicts poor prognosis in EGFR mutant lung adenocarcinoma patients, through the cell cycle-regulated U2AF2 RNA splicing. 95%
- Multidimensional Characterization of Soft-Tissue Sarcomas with FUS-TFCP2 or EWSR1-TFCP2 Fusions 94%
- Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid. 93%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.